Sexual Health
Overview
Peptide therapy for sexual health addresses both the physical (vasculogenic, hormonal) and neurological components of sexual function. These peptides work centrally via melanocortin receptors (PT-141, Melanotan II), through the HPG axis (Kisspeptin-10, Gonadorelin, Triptorelin), and via social bonding pathways (Oxytocin). Unlike PDE5 inhibitors, central-acting peptides address desire and arousal rather than just mechanics.
Recommended Peptides
- PT-141 (Bremelanotide) – melanocortin MC4R agonist acting centrally to increase sexual desire and arousal; FDA-approved for HSDD in women; effective in men unresponsive to PDE5 inhibitors
- Kisspeptin-10 – hypothalamic neuropeptide triggering LH/FSH release; supports testosterone and estrogen production; studied for desire and reproductive health
- Oxytocin – the bonding hormone; enhances sexual pleasure, orgasm intensity, and emotional connection; intranasal administration
- Melanotan II – non-selective melanocortin agonist; potent pro-erectile and pro-arousal effects; also causes tanning; more side effects than PT-141
- Gonadorelin – GnRH analogue used to maintain testicular function and endogenous testosterone production; often used alongside TRT
- Triptorelin – GnRH agonist/antagonist (dose-dependent); used for post-TRT HPG axis restart and in fertility protocols
Protocols
Related Conditions
Research Summary
The melanocortin pathway is central to sexual health peptide therapy. PT-141/Vyleesi is the only FDA-approved peptide for HSDD (PMID-31599840). Kisspeptin modulates sexual brain processing in both women (PMID-36287566) and men (PMID-36735255). GnRH agonists/antagonists are standard of care for prostate and breast cancer but impact sexual function through androgen suppression. HCG maintains testicular function and fertility during TRT protocols.
Related
#condition #reproductive